60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
December 11, 2024 08:56 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 14, 2024 14:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
October 03, 2024 09:02 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 04, 2024 08:00 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent.
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
August 14, 2024 11:01 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
August 12, 2024 09:12 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
July 25, 2024 09:02 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K.
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
May 30, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.